Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes

Blood

Volumn 118, Issue 19, 2011, Pages 5174-5177

  Hofmann, Christian ^a   Höfflin, Sandra ^a   Hückelhoven, Angela ^a   Bergmann, Silke ^a   Harrer, Ellen ^a   Schuler, Gerold ^a,b   Dörrie, Jan ^a   Schaft, Niels ^a   Harrer, Thomas ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; HLA ANTIGEN; HLA B13 ANTIGEN; RNA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SELECTION; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL EXPRESSING TWO ADDITIONAL RECEPTOR; T LYMPHOCYTE;

EID: 81055149608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-347005     Document Type: Article

References (25)

1. Hawkins RE, Gilham DE, Debets R, et al. Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther. 2010;21(6):665-672.
2. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2(7):512-519. (Pubitemid 37328742)
3. Birkholz K, Hombach A, Krug C, et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009;16(5):596-604.
4. Birkholz K, Hofmann C, Hoyer S, et al. A fast and robust method to clone and functionally validate T-cell receptors. J Immunol Methods. 2009;346(1-2):45-54.
5. Hofmann C, Harrer T, Kubesch V, et al. Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA. AIDS. 2008;22(13):1577-1582.
6. Schaft N, Dorrie J, Muller I, et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother. 2006;55(9):1132-1141. (Pubitemid 43800728)
7. Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J Immunother. 2006;29(4):398-406. (Pubitemid 44288952)
8. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129. (Pubitemid 44547756)
9. Moore CB, John M, James IR, et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 2002;296(5572):1439-1443. (Pubitemid 34553083)
10. Allen TM, Altfeld M, Geer SC, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol. 2005;79(21):13239-13249. (Pubitemid 41508139)
11. Feeney ME, Tang Y, Roosevelt KA, et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol. 2004;78(16):8927-8930. (Pubitemid 39025159)
12. Maurer K, Harrer EG, Goldwich A, et al. Role of cytotoxic T-lymphocyte-mediated immune selection in a dominant human leukocyte antigen-B8-restricted cytotoxic T-lymphocyte epitope in Nef. J Acquir Immune Defic Syndr. 2008;48(2):133-141.
13. Koenig S, Conley AJ, Brewah YA, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med. 1995;1(4):330-336.
14. Marchand M, Brichard V, van Baren N, Coulie PG. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther. 2001;1(3):497-510. (Pubitemid 33768665)
15. van Loenen MM, Hagedoorn RS, Kester MG, et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res. 2009;69(5):2034-2041.
16. Langerman A, Callender GG, Nishimura MI. Retroviral transduction of peptide stimulated T cells can generate dual T cell receptor-expressing (bifunctional) T cells reactive with two defined antigens. J Transl Med. 2004;2(1):42.
17. Brander C, Yang OO, Jones NG, et al. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J Virol. 1999;73(12):10191-10198.
18. Harrer EG, Bergmann S, Eismann K, et al. A conserved HLA B13-restricted cytotoxic T lymphocyte epitope in Nef is a dominant epitope in HLA B13-positive HIV-1-infected patients. AIDS. 2005;19(7):734-735. (Pubitemid 40593081)
19. Kolowos W, Schmitt M, Herrman M, et al. Biased TCR repertoire in HIV-1-infected patients due to clonal expansion of HIV-1-reverse transcriptase-specific CTL clones. J Immunol. 1999;162(12):7525-7533. (Pubitemid 29277733)
20. Birkholz K, Schwenkert M, Kellner C, et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood. 2010;116(13):2277-2285.
21. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006;66(17):8878-8886. (Pubitemid 44449206)
22. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242(4882):1171-1173. (Pubitemid 19007043)
23. Drake DR III, Ream RM, Lawrence CW, Braciale TJ. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function. J Immunol. 2005;175(3):1507-1515. (Pubitemid 41023051)
24. Gladow M, Uckert W, Blankenstein T. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur J Immunol. 2004;34(7):1882-1891. (Pubitemid 39256070)
25. Hah C, Kim M, Kim K. Induction of peripheral tolerance in dual TCR T cells: an evidence for nondominant signaling by one TCR. J Biochem Mol Biol. 2005;38(3):334-342. (Pubitemid 43034375)